Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5276166
Max Phase: Preclinical
Molecular Formula: C24H57Na13O60S13
Molecular Weight: 1709.43
Associated Items:
ID: ALA5276166
Max Phase: Preclinical
Molecular Formula: C24H57Na13O60S13
Molecular Weight: 1709.43
Associated Items:
Canonical SMILES: O=S(=O)(O)OC[C@H]1O[C@@H](O)[C@H](OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H]1O[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@H]2O[C@H](COS(=O)(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]1O[SH](=O)(O)O.[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].[NaH]
Standard InChI: InChI=1S/C24H44O60S13.13Na.13H/c25-21-17(81-94(53,54)55)13(77-90(41,42)43)9(5(69-21)1-65-85(26,27)28)73-22-18(82-95(56,57)58)14(78-91(44,45)46)10(6(70-22)2-66-86(29,30)31)74-23-19(83-96(59,60)61)15(79-92(47,48)49)11(7(71-23)3-67-87(32,33)34)75-24-20(84-97(62,63)64)16(80-93(50,51)52)12(76-89(38,39)40)8(72-24)4-68-88(35,36)37;;;;;;;;;;;;;;;;;;;;;;;;;;/h5-25,95H,1-4H2,(H,26,27,28)(H,29,30,31)(H,32,33,34)(H,35,36,37)(H,38,39,40)(H,41,42,43)(H,44,45,46)(H,47,48,49)(H,50,51,52)(H,53,54,55)(H2,56,57,58)(H,59,60,61)(H,62,63,64);;;;;;;;;;;;;;;;;;;;;;;;;;/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17-,18-,19-,20-,21-,22-,23-,24-;;;;;;;;;;;;;;;;;;;;;;;;;;/m1........................../s1
Standard InChI Key: LRSWTNPEWMSTJM-YCXLYQHCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1709.43 | Molecular Weight (Monoisotopic): 1707.6761 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Fu K, Bai Z, Chen L, Ye W, Wang M, Hu J, Liu C, Zhou W.. (2020) Antitumor activity and structure-activity relationship of heparanase inhibitors: Recent advances., 193 [PMID:32222663] [10.1016/j.ejmech.2020.112221] |
Source(1):